Daclizumab Subcutaneous and Fiorinal w/Codeine

• Generic Name: daclizumab
• Dosage Forms: n.a.
• Other Brand Names: Zinbryta, Zenapax

Daclizumab injection is used to treat the relapsing forms of multiple sclerosis (MS). Daclizumab will not cure MS, but it may slow some of the disabling effects and decrease the number of relapses of the disease. It should only be used when other medicines to treat MS did not work well.

Daclizumab was available only under a restricted distribution program called the Zinbryta® REMS (Risk Evaluation and Mitigation Strategy) Program.

Daclizumab was voluntarily withdrawn from the worldwide market on March 2, 2018 due to safety concerns.

• Generic Name: aspirin / butalbital / caffeine / codeine
• Dosage Forms: n.a.
• Other Brand Names: Ascomp with Codeine, Fiorinal with Codeine, Fiortal with Codeine, Ascomp-Codeine, Fiorinal/Codeine #3

Butalbital, aspirin, caffeine, and codeine combination is used to relieve symptoms of tension (or muscle contraction) headaches. Extended and repeated use of this product is not recommended.

Butalbital belongs to the group of medicines called barbiturates. Barbiturates act in the central nervous system (CNS) to produce their effects.

Aspirin is used to relieve pain and reduce fever in patients. It belongs to the group of medicines known as salicylates and acts on the immune system to reduce inflammation. It is also known as an anti-inflammatory analgesic.

Caffeine is a CNS stimulant that is used with pain relievers to increase their effect. It has also been used for migraine headaches. Codeine belongs to the group of medicine called narcotic analgesics (pain medicines). It acts on the central nervous system (CNS) to relieve pain.

When butalbital or codeine is used for a long time or in large doses, it may become habit-forming, causing mental or physical dependence. Physical dependence may lead to withdrawal side effects when you suddenly stop taking the medicine. In patients who get headaches, the first symptom of withdrawal may be new (rebound) headaches.

This medicine is available only under a restricted distribution program called the Opioid Analgesic REMS (Risk Evaluation and Mitigation Strategy) program.